AMC Stock After Record Earnings: Buy, Sell, or Hold?

AMC’s print is a genuine operating inflection, but the equity still trades like a stressed capital structure with a call option on continued box-office strength. The market is likely over-assigning near-term EBITDA improvement to equity value while under-weighting that most incremental cash generation will first de-risk debt, not re-rate the common; that keeps upside capped unless multiple quarters confirm free-cash-flow durability.

The better second-order winner is likely higher-quality exhibition exposure, especially CNK and IMAX, which can participate in attendance upside without AMC’s dilution overhang and equity subordination. On the other side, the biggest loser is AMC’s own common if management uses strength to term out debt but then reopens the equity at higher prices; repeated supply would pressure the stock even if operations continue improving. Studios with strong theatrical slates and premium-format suppliers gain, but the key question is whether this is a one-quarter rebound or the start of a normal earnings power reset.

Catalyst-wise, the next 1-3 months matter more than the next 1-3 years: Q3 should tell us whether operating leverage persists as the slate normalizes and whether interest savings actually flow through to FCF. The contrarian risk is that consensus is treating the move as a dead-cat bounce when leverage cuts and a heavy release calendar could produce another positive surprise; if AMC posts another quarter of double-digit revenue growth and positive FCF, the short thesis weakens materially. Falsifiers are straightforward: sustained positive FCF, no further dilution, and guidance that implies deleveraging faster than expected; absent that, the common remains a trading vehicle rather than a compounding asset.